Novel treatment options for refractory Germ Cell Tumours: back to the bench!

C Kollmannsberger¹, L Nappi^{1

2}, C Nichols^{3

4}

Affiliations

¹ Division of Medical Oncology, British Columbia Cancer - Vancouver Cancer Centre, University of British Columbia, Vancouver, Canada.
² Vancouver Prostate Center, Department of Urologic Science, University of British Columbia, Vancouver, Canada.
³ Testicular Cancer Commons, Portland, USA.
⁴ Southwest Oncology Group, SWOG Group Office, Marquam II, Knight Cancer Institute, Oregon Health & Science University, Portland, USA.

Free article

Comment

C Kollmannsberger et al. Ann Oncol. 2018.

Free article

. 2018 Jan 1;29(1):21-22.

doi: 10.1093/annonc/mdx746.

C Kollmannsberger¹, L Nappi^{1

2}, C Nichols^{3

4}

¹ Division of Medical Oncology, British Columbia Cancer - Vancouver Cancer Centre, University of British Columbia, Vancouver, Canada.
² Vancouver Prostate Center, Department of Urologic Science, University of British Columbia, Vancouver, Canada.
³ Testicular Cancer Commons, Portland, USA.
⁴ Southwest Oncology Group, SWOG Group Office, Marquam II, Knight Cancer Institute, Oregon Health & Science University, Portland, USA.

No abstract available

Comment on

Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206.
Adra N, Einhorn LH, Althouse SK, Ammakkanavar NR, Musapatika D, Albany C, Vaughn D, Hanna NH. Adra N, et al. Ann Oncol. 2018 Jan 1;29(1):209-214. doi: 10.1093/annonc/mdx680. Ann Oncol. 2018. PMID: 29045540 Clinical Trial.